19 June 2013
Keywords: ceresine, gains, orphan, status, cypros, pharmaceutical, cpc-211
Article | 01 July 1999
Cypros Pharmaceutical's Ceresine (CPC-211) has been granted orphandrug status by the US Food and Drug Administration for the treatment of
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 February 1999
18 June 2013
© 2013 thepharmaletter.com